17,701 Shares in Palvella Therapeutics, Inc. $PVLA Bought by XTX Topco Ltd

XTX Topco Ltd bought a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the second quarter, HoldingsChannel.com reports. The firm bought 17,701 shares of the company’s stock, valued at approximately $399,000.

A number of other large investors have also recently added to or reduced their stakes in PVLA. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Palvella Therapeutics in the 2nd quarter valued at about $37,000. JPMorgan Chase & Co. grew its holdings in shares of Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after buying an additional 3,242 shares in the last quarter. Rhumbline Advisers acquired a new stake in Palvella Therapeutics in the 2nd quarter valued at approximately $224,000. Goldman Sachs Group Inc. bought a new stake in Palvella Therapeutics in the 1st quarter valued at approximately $533,000. Finally, AWM Investment Company Inc. acquired a new position in Palvella Therapeutics during the 1st quarter worth approximately $1,943,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Price Performance

Shares of PVLA stock opened at $100.49 on Friday. The stock has a market cap of $1.19 billion, a P/E ratio of -38.21 and a beta of -0.20. The company has a fifty day moving average price of $79.88 and a two-hundred day moving average price of $52.31. Palvella Therapeutics, Inc. has a one year low of $11.17 and a one year high of $106.71.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.18). As a group, equities research analysts anticipate that Palvella Therapeutics, Inc. will post -3.69 EPS for the current fiscal year.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $86.23, for a total transaction of $370,961.46. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 20.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PVLA. Weiss Ratings reiterated a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday, December 1st. Craig Hallum started coverage on shares of Palvella Therapeutics in a research note on Thursday. They issued a “buy” rating and a $175.00 price target on the stock. Raymond James Financial upgraded shares of Palvella Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $92.00 to $143.00 in a research note on Wednesday, November 19th. BTIG Research initiated coverage on Palvella Therapeutics in a report on Friday. They issued a “buy” rating and a $167.00 price objective for the company. Finally, Oppenheimer reiterated an “outperform” rating on shares of Palvella Therapeutics in a report on Tuesday, November 11th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $125.00.

Palvella Therapeutics Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.